Atara Biotherapeutics (NASDAQ:ATRA) Rating Increased to Strong-Buy at TD Cowen

Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by equities research analysts at TD Cowen to a “strong-buy” rating in a report released on Friday,Zacks.com reports.

A number of other equities analysts also recently commented on ATRA. Canaccord Genuity Group increased their price objective on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a report on Wednesday, August 21st. Finally, Mizuho upgraded Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and decreased their price target for the company from $25.00 to $18.00 in a research note on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.67.

Atara Biotherapeutics Stock Performance

Shares of Atara Biotherapeutics stock opened at $12.18 on Friday. The firm has a market cap of $70.13 million, a PE ratio of -0.47 and a beta of 0.50. The business’s 50 day simple moving average is $9.54 and its 200 day simple moving average is $10.03. Atara Biotherapeutics has a 52-week low of $6.50 and a 52-week high of $39.50.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, topping analysts’ consensus estimates of ($3.77) by $0.84. The business had revenue of $40.19 million during the quarter, compared to the consensus estimate of $23.00 million. During the same period in the prior year, the firm earned ($16.50) EPS. As a group, equities research analysts predict that Atara Biotherapeutics will post -12.12 EPS for the current year.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. bought a new position in Atara Biotherapeutics during the second quarter worth about $53,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Atara Biotherapeutics in the second quarter valued at approximately $79,000. State Street Corp boosted its stake in shares of Atara Biotherapeutics by 52.3% during the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after acquiring an additional 7,680 shares during the period. FMR LLC increased its holdings in shares of Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 7,381 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Atara Biotherapeutics by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after acquiring an additional 4,043 shares during the period. 70.90% of the stock is owned by institutional investors.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.